Diane Ethier
TransCanada (Canada)(CA)Merck Canada Inc. (Canada)(CA)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Asthma and respiratory diseases, Estrogen and related hormone effects, Synthesis and biological activity, Protease and Inhibitor Mechanisms
Most-Cited Works
- → Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2(2001)457 cited
- → The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor(1999)427 cited
- → Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles(1999)398 cited
- → 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.(1993)395 cited
- → Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor(1997)326 cited
- → Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530(1998)271 cited